Characteristics of the subjects in cohort 1
| Control never-smokers | Control ex-smokers | COPD ex-smokers | |
|---|---|---|---|
| Subjects (n) | 20 | 23 | 69 |
| Men/women | 9/11 | 20/3** | 66/3*** |
| Age (years) | 70.2±8.0 | 68.0±6.2 | 71.7±6.8 |
| BMI (kg/m2) | 22.7±2.4 | 23.8±2.3 | 22.9±3.8 |
| Smoking (pack-years) | 0 | 49.6±30*** | 56.1±21*** |
| FVC (%pred) | 108.0±13 | 103.6±10 | 90.4±22**† |
| FEV1 (%pred) | 109.3±14 | 99.4±12 | 57.5±24***††† |
| FEV1/FVC (%) | 80.4±5.2 | 78.0±4.9 | 50.4±15***††† |
| DLCO (%pred) | 125.5±25 | 107.5±27 | 70.9±33***††† |
| DLCO/VA (%pred) | 106.2±14 | 96.8±15 | 65.8±30***††† |
| GOLD (I/II/III/IV) | NA | NA | 13/30/15/11 |
| LABA | NA | NA | 44 |
| LAMA | NA | NA | 32 |
| ICS | NA | NA | 16 |
| Theophylline | NA | NA | 18 |
Data are presented as mean±SD.
**p<0.01, ***p<0.001 compared with control never-smokers; †p<0.05, †††p<0.001 compared with control ex-smokers.
BMI, body mass index; DLCO, diffusing capacity of the lung for carbon monoxide; FEV1%pred, % predicted values of FEV1; GOLD, Global Initiative for Chronic Obstructive Lung Disease; ICS, inhaled corticosteroids; LABA, long-acting β2 agonist; LAMA, long-acting muscarinic antagonist; NA, not applicable; VA, alveolar volume.